• A Phase III clinical trial demonstrates that a combination of amlodipine and candesartan is more effective than amlodipine alone in reducing diastolic blood pressure in hypertensive patients.
• The study, involving Korean patients with essential hypertension, showed significant reductions in both diastolic and systolic blood pressure with the combination therapy.
• The fixed-dose combination of amlodipine and candesartan was well-tolerated, with adverse events comparable to those observed with amlodipine monotherapy.
• These findings support the use of amlodipine and candesartan combination therapy as an effective treatment option for patients whose hypertension is not adequately controlled by amlodipine alone.